An open, multicenter phase II trial evaluating the antitumour efficacy of Faslodex (fulvestrant) in postmenopausal women with advanced breast cancer failing non-steroidal or steroidal aromatase inhibitors

Trial Profile

An open, multicenter phase II trial evaluating the antitumour efficacy of Faslodex (fulvestrant) in postmenopausal women with advanced breast cancer failing non-steroidal or steroidal aromatase inhibitors

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2007

At a glance

  • Drugs Fulvestrant (Primary)
  • Indications Advanced breast cancer; Menopause
  • Focus Therapeutic Use
  • Acronyms SAKK
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top